NCT02819583 2016-10-25
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.